Acadian Asset Management’s Pliant Therapeutics PLRX Stock Holding History

Acadian Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.04M	Buy	2,416,508 +51,839	+2%	+$65.4K	﹤0.01%	835
2025 Q4	$2.88M	Sell	2,364,669 -4,873	-0.2%	-$7.32K	﹤0.01%	817
2025 Q3	$3.5M	Buy	2,369,542 +739,129	+45%	+$1.13M	0.01%	744
2025 Q2	$1.88M	Buy	1,630,413 +409,967	+34%	+$579K	﹤0.01%	846
2025 Q1	$1.64M	Buy	+1,220,446	New	+$7.41M	﹤0.01%	809
2022 Q3	–	Sell	-10,753	Closed	-$86K	–	1802
2022 Q2	$86K	Buy	10,753 +6,663	+163%	+$42.7K	﹤0.01%	1387
2022 Q1	$27K	Buy	+4,090	New	+$41.7K	﹤0.01%	1536

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Acadian Asset Management's PLRX Position: Q1 2026 in Review

Acadian Asset Management increased its Pliant Therapeutics (PLRX) stake by 2.2% in Q1 2026, buying an estimated $65.4K and bringing the position to 2,416,508 shares worth $3.04M. The position accounts for ﹤0.01% of the portfolio, ranked #835.

Acadian Asset Management first reported a position in PLRX in Q1 2022 and has held it in 7 quarters since. The position peaked at $3.5M in Q3 2025. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

Acadian Asset Management held 2,416,508 shares of Pliant Therapeutics worth $3.04M as of Q1 2026.
Acadian Asset Management bought 51,839 Pliant Therapeutics shares in Q1 2026, an estimated $65.4K.
Pliant Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #835 holding.
Acadian Asset Management first reported a position in Pliant Therapeutics in Q1 2022 and has held it in 7 quarters since.
Acadian Asset Management's Pliant Therapeutics position peaked at $3.5M in Q3 2025.
91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.